282 related articles for article (PubMed ID: 33256902)
1. Pharmacogenomics and ALL treatment: How to optimize therapy.
Karol SE; Yang JJ
Semin Hematol; 2020 Jul; 57(3):130-136. PubMed ID: 33256902
[TBL] [Abstract][Full Text] [Related]
2. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.
Liang DC; Yang CP; Liu HC; Jaing TH; Chen SH; Hung IJ; Yeh TC; Lin TH; Lai CL; Lai CY; Shih LY
Pharmacogenomics J; 2016 Nov; 16(6):536-539. PubMed ID: 26503813
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in acute lymphoblastic leukemia.
Lee SHR; Yang JJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):229-236. PubMed ID: 29050696
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of Thiopurine Pharmacogenomics in Pediatrics.
Pavlovic S; Kotur N; Stankovic B; Gasic V; Lucafo M; Decorti G; Zukic B
Curr Drug Metab; 2020; 21(1):53-62. PubMed ID: 32124692
[TBL] [Abstract][Full Text] [Related]
5. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
Kager L
J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
[TBL] [Abstract][Full Text] [Related]
6. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
[TBL] [Abstract][Full Text] [Related]
7. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S; Marable M; Huang RS
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenomics for leukemia treatment].
Tanaka Y
Rinsho Ketsueki; 2016 Jul; 57(7):910-8. PubMed ID: 27498738
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.
Relling MV; Ramsey LB
Hematology Am Soc Hematol Educ Program; 2013; 2013():126-30. PubMed ID: 24319173
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.
Mei L; Ontiveros EP; Griffiths EA; Thompson JE; Wang ES; Wetzler M
Blood Rev; 2015 Jul; 29(4):243-9. PubMed ID: 25614322
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics: The right drug for you.
Drew L
Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
[No Abstract] [Full Text] [Related]
12. [Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia].
He J; Liu L
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jan; 21(1):100-104. PubMed ID: 30675872
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics in the clinic.
Relling MV; Evans WE
Nature; 2015 Oct; 526(7573):343-50. PubMed ID: 26469045
[TBL] [Abstract][Full Text] [Related]
15. Pediatric acute lymphoblastic leukemia.
Carroll WL; Bhojwani D; Min DJ; Raetz E; Relling M; Davies S; Downing JR; Willman CL; Reed JC
Hematology Am Soc Hematol Educ Program; 2003; ():102-31. PubMed ID: 14633779
[TBL] [Abstract][Full Text] [Related]
16. The challenges of implementing pharmacogenomic testing in the clinic.
Moyer AM; Caraballo PJ
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):567-577. PubMed ID: 28949250
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
19. Star Allele-Based Haplotyping versus Gene-Wise Variant Burden Scoring for Predicting 6-Mercaptopurine Intolerance in Pediatric Acute Lymphoblastic Leukemia Patients.
Park Y; Kim H; Choi JY; Yun S; Min BJ; Seo ME; Im HJ; Kang HJ; Kim JH
Front Pharmacol; 2019; 10():654. PubMed ID: 31244663
[No Abstract] [Full Text] [Related]
20. Pharmacogenetics in acute lymphoblastic leukemia.
Cheok MH; Pottier N; Kager L; Evans WE
Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
